Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
|2||Active, not recruiting||
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
† Study has passed its completion date and status has not been verified in more than two years.